Moleculin Biotech Earnings Call Transcripts
Fiscal Year 2026
-
The MIRACLE phase III trial for relapsed/refractory AML is progressing rapidly, with interim unblinded data for 45 patients expected soon. Annamycin shows strong efficacy, zero cardiotoxicity, and broad organ targeting, positioning it for significant market impact and multiple upcoming milestones.
-
Leadership highlighted deep experience and investment, with Annamycin positioned as a non-cardiotoxic, next-generation anthracycline. Phase 2 data showed strong remission rates in AML, and the adaptive Phase 3 MIRACLE trial offers near-term data visibility and significant market potential.
Fiscal Year 2025
-
Annamycin demonstrated promising efficacy and safety in a phase 1B/2 trial for advanced STS lung metastases, with median OS of 13.5 months overall and nearly 20 months in optimally dosed second-line patients, and no observed cardiotoxicity.
-
Phase III MIRACLE trial for Annamycin in AML is underway globally, with EMA and FDA approvals advancing and first patient treated. Cash runway extends into Q3 2025, with $15M more needed for key milestones. Interim data readouts and final MD-107 results are expected soon.
Fiscal Year 2024
-
MIRACLE phase 3 trial for Annamycin in AML is underway with strong phase 2 results and multiple interim data readouts planned. Financially, $13M in cash extends runway into Q3 2025, with increased burn expected in 2026. Annamycin shows promise as a non-cardiotoxic anthracycline.
-
MIRACLE phase III trial for Annamycin in AML shows strong early efficacy, with a 50% CR rate and median survival over seven months, while financials support operations into Q1 2025. Adaptive trial design and global site engagement aim to accelerate data milestones.
-
Annamycin, a non-cardiotoxic anthracycline, shows a 50% CR rate in second-line AML, far exceeding current therapies. The pivotal Miracle trial will compare two dosing regimens to HiDAC, with interim data expected in late 2025 and unblinded results in mid-2026.
-
Annamycin, a next-generation anthracycline, shows superior efficacy and no cardiotoxicity in AML, with pivotal phase 3 trials set to begin. Regulatory support, strong clinical data, and a robust financial position highlight significant market and patient impact.
-
Annamycin, a novel anthracycline, has shown promising efficacy and safety in relapsed/refractory AML, with a 50% complete remission rate and no observed cardiotoxicity. The adaptive phase III MIRACLE trial, starting in Q1 2025, aims to confirm these results and expedite regulatory approval.